We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-2.50 | -2.38% | 102.50 | 100.00 | 105.00 | 105.00 | 102.50 | 105.00 | 8,542 | 10:19:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -4.80 | 14M |
TIDMFDBK
RNS Number : 4187E
Feedback PLC
05 November 2020
Feedback plc
Result of Annual General Meeting
London, UK, 5 November 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that at its annual general meeting held earlier today, all resolutions were duly passed on a poll. The proxy voting results of the resolutions are included below.
Resolutions Votes For* % of Votes % of Votes Total votes votes Against votes Withheld** cast** cast** cast** 1. To receive and adopt the annual report and accounts for the year ended 31 May 2020 504,134,927 100.00% - 0.00% 22,000 503,044,792 ------------ -------- ---------- -------- ------------ ----------- 2. To elect Adam Denning as a director 504,152,622 100.00% 3,305 0.00% 1,000 503,065,534 ------------ -------- ---------- -------- ------------ ----------- 3. To elect Philipp Prince as a director 479,902,622 95.19% 24,253,305 4.81% 1,000 503,065,534 ------------ -------- ---------- -------- ------------ ----------- 4. To re-elect Simon Sturge as a director 504,152,486 100.00% 3,441 0.00% 1,000 503,065,670 ------------ -------- ---------- -------- ------------ ----------- 5. To appoint Price Bailey LLP as auditors of the Company 504,118,963 99.99% 36,964 0.01% 1,000 503,099,193 ------------ -------- ---------- -------- ------------ ----------- 6. To authorise the directors to allot relevant securities equivalent to up to two thirds of the Company's issued share capital, subject to certain conditions 504,027,372 100.00% 3,305 0.00% 126,250 502,940,284 ------------ -------- ---------- -------- ------------ ----------- 7. To authorise the directors to allot relevant securities equivalent to up to 10 per cent. of the Company's issued share capital on a non-pre-emptive basis subject to certain conditions 478,945,731 95.01% 25,135,091 4.99% 76,205 502,990,429 ------------ -------- ---------- -------- ------------ -----------
Notes:
* "Votes For" include votes giving the Chairman discretion.
** "Votes Withheld" are not votes in law and do not count in the number of votes counted for or against a resolution, or towards the total votes cast.
-Ends-
Enquiries:
Feedback plc +44 (0)1954 718072 Tom Oakley, CEO IR@fbk.com Lindsay Melvin, CFO Allenby Capital Limited (Nominated Adviser) David Worlidge / Asha Chotai +44 (0)20 3328 5656 Peterhouse Capital Limited (Joint Broker) Lucy Williams / Duncan Vasey +44 (0)20 7469 0936 Stanford Capital Partners Limited (Joint Broker) Patrick Claridge / John Howes +44 20 3815 8880 Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com Paul McManus/Nick Rome/Nicholas 07980 541 893 or 07748 325 236 or Johnson 07884 664 686
Notes to Editors
Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGXELFBBFLLFBL
(END) Dow Jones Newswires
November 05, 2020 08:23 ET (13:23 GMT)
1 Year Feedback Chart |
1 Month Feedback Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions